Crown Healthcare, a Nairobi-based medical distribution company led by Kenyan entrepreneur Shilen Thakerar, has secured a $10 million investment to build a large-scale pharmaceutical manufacturing facility, marking a significant step in Kenya’s push to strengthen local drug production and reduce reliance on imports. The funding, provided by Impact Fund Denmark, comes as African governments and investors increasingly prioritize domestic manufacturing to protect health systems from global supply chain shocks and rising medicine costs.
The new facility will transform Crown Healthcare from a medical distributor into a fully integrated pharmaceutical manufacturer, enabling it to produce essential generic medicines locally. This shift is expected to shorten delivery times, improve supply reliability, and make quality-assured medicines more accessible to public hospitals and private healthcare providers across Kenya and the wider East African region. The plant will also include logistics, quality control, and technical operations, and is projected to create around 600 jobs once fully operational.
Impact Fund Denmark said the investment aligns with its mandate to support sustainable healthcare manufacturing in emerging markets and build resilience against disruptions such as those experienced during the COVID-19 pandemic. For Kenya, where an estimated 80 percent of pharmaceuticals are imported, the project addresses long-standing vulnerabilities including supply delays, foreign exchange pressures, and exposure to counterfeit drugs.
Counterfeit medicines remain a serious challenge across Africa, particularly for high-demand treatments such as antibiotics, antimalarials, antiretrovirals, and painkillers. By expanding local production, Crown Healthcare aims to improve regulatory oversight and product traceability, while supporting national efforts to safeguard drug quality and patient safety.
Founded in 1998, Crown Healthcare has built a strong footprint across Kenya, Nigeria, Tanzania, Uganda, and Rwanda, growing from a regional distributor into a supplier of branded generic medicines. The planned manufacturing plant represents the company’s most ambitious expansion to date and signals its evolution into a regional pharmaceutical producer.
The investment reflects growing confidence among development financiers that pharmaceutical manufacturing in Africa can be both commercially viable and socially impactful. If successfully executed, the project could play a meaningful role in advancing Kenya’s goal of medicine self-sufficiency while positioning Crown Healthcare as a key player in East Africa’s pharmaceutical value chain.
